The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.
He expects more visibility on Amgen’s launch plans for Imdelltra (tarlatamab) and growth strategy for key products like Tepezza and Krystexxa. JPMorgan’s Chris Schott also expects trial ...
Zacks.com on MSN21d
Amgen Gears Up to Report Q3 Earnings: Here's What to ExpectAmgen AMGN will report third-quarter 2024 results ... respectively. Imdelltra (tarlatamab), approved for pre-treated advanced ...
Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products ...
Amgen AMGN reported third-quarter 2024 adjusted ... up 88% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024 ...
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...
Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...
Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - ...
Additionally, tarlatamab has shown efficacy in treating patients with brain metastases, further strengthening Amgen's position in the oncology market. Enbrel, one of Amgen's established products, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback